|
|
 |
|
Viewing report
|
|
|
|
Onyx Pharmaceuticals Incorporated
Sheila Greco Associates, May 2011, Pages: 1
Onyx Pharmaceuticals is developing innovative small molecule cancer treatments based on a molecular understanding of cancer. Our lead product is Nexavar? (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). Nexavar has been approved by the U.S. Food and Drug Administration for the treatment of patients with advanced kidney cancer. This product is being developed in collaboration with Bayer Pharmaceuticals Corporation. The companies also have pivotal trials underway in metastatic melanoma, in advanced primary liver cancer, and in non-small cell lung cancer. In addition, the agent is being studied in multiple Phase II trials, as well as in several Phase Ib studies evaluating its use in combination with standard chemotherapies and other anticancer agents. We also have a small molecule cell cycle inhibitor resulting from a collaboration with Pfizer that entered clinical testing in 2004.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
